Table 1.
Clinical and demographic characteristics of MS patients at the date of the 1st dose of COVID-19 vaccine or COVID-9 onset.
| Vaccinated | Post-COVID-19 | |
|---|---|---|
| Study population | 1661 | 495 |
| Age, mean (SD), y | 48.49 (11.43) | 45.84 (11.00) |
| <55 | 1188 (71.52%) | 382 (77.17%) |
| >=55 | 473 (28.48%) | 113 (22.83%) |
| Female | 1202 (72.37%) | 365 (73.74%) |
| MS duration (SD), y | 17.33 (10.22) | 15.44 (9.46) |
| EDSS1 | ||
| EDSS < 4 | 1029 (63.44%) | 342 (70.95%) |
| EDSS >= 4 | 593 (36.56%) | 140 (29.05%) |
| DMT | 1259 (75.80%) | 396 (80.00%) |
| Interferons | 343 (20.53%) | 96 (19.39%) |
| Glatiramer acetate | 129 (7.77%) | 47 (9.49%) |
| Teriflunomide | 92 (5.54%) | 30 (6.06%) |
| Dimethyl fumarate | 92 (5.54%) | 22 (4.44%) |
| Natalizumab | 103 (6.20%) | 42 (8.48%) |
| Fingolimod | 273 (16.44%) | 79 (15.96%) |
| Ocrelizumab | 122 (7.34%) | 46 (9.29%) |
| Rituximab | 26 (1.57%) | 8 (1.62%) |
| Alemtuzumab | 19 (1.14%) | 6 (1.21%) |
| Cladribine | 60 (3.61%) | 20 (4.04%) |
| No DMT | 402 (24.20%) | 99 (20.00%) |
| COVID-19 vaccine | ||
| BNT162b2 (Comirnaty) – mRNA | 1495 (90.01%)2 | |
| Time between doses (SD), d | 38.47 (13.13) | |
| mRNA-1273 (Spikevax) – mRNA | 96 (5.78%)3 | |
| Time between doses (SD), d | 36.45 (8.22) | |
| AZD1222 (Vaxzevria) – vector | 57 (3,43%)4 | |
| Time between doses (SD), d | 76.86 (16.83) | |
| Gam-COVID-Vac (Sputnik V) – vector | 1 (0.06%)5 | |
| Time between doses, d | 21 | |
| Ad26.COV2.S (Janssen) – vector | 12 (0.72%) | |
| COVID-19 severity | ||
| Death | 1 (0.20%) | |
| Need of invasive ventilation or extracorporeal membrane oxygenation | 2 (0.40%) | |
| Need of non-invasive ventilation or high-flow oxygen therapy | 9 (1.82%) | |
| Need of supplemental oxygen | 11 (2.22%) | |
| Radiologically confirmed pneumonia | 25 (5.05%) | |
| Suspected pneumonia (dry cough, fever and shortness of breath) | 45 (9.09%) | |
| Symptomatic | 389 (78.59%) | |
| Asymptomatic | 13 (2.63%) | |
MS = multiple sclerosis; EDSS = expanded disability status scale; DMT = disease-modifying treatment; 1. EDSS is not available for all individuals, the percentage corresponds to the proportion of patients with a known value; 2. 1477 (98,80%) patients got 2 doses of the vaccine; 3. all patients got 2 doses of the vaccine; 4. 56 (98.25%) patients got 2 doses of the vaccine; 5. 2 (66.67%) patients got 2 doses of the vaccine.